ABL1 and malignant colon neoplasm: We demonstrated in our previous publication that the engraft protein drug PMIBcr/Abl‐R6 could penetrate into the cytoplasm, interact with MDM2 with high affinity, and activate p53‐related apoptosis in Tp53 wild‐type colon cancer cells in vivo in a xenograft mouse model, showing great stability and low immunogenicity and toxicity both in vitro and in vivo.[21]